In particular, the use of a monoclonal anti-HMGB1 Ab has been shown to be effective in treating central nervous system disorders such as stroke, traumatic brain injury, Parkinson’s disease, or Alzheimer’s disease [39]. This evidence concerns the gene HMGB1 and early-onset autosomal dominant Alzheimer disease.